Epigenetics in Reactive and Reparative Cardiac Fibrogenesis: The Promise of Epigenetic Therapy

Journal of Cellular Physiology

Volumn 232, Issue 8, 2017, Pages 1941-1956

  Ghosh, Asish K ^a   Rai, Rahul ^a   Flevaris, Panagiotis ^a   Vaughan, Douglas E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; DNA DEMETHYLASE; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE; MICRORNA; MICRORNA 1; MICRORNA 125B; MICRORNA 133A; MICRORNA 150; MICRORNA 155; MICRORNA 208A; MICRORNA 21; MICRORNA 214; MICRORNA 29A; MICRORNA 30C; MICRORNA LET 7C; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; COLLAGEN; GENETIC MARKER;

AGING; CARDIAC MUSCLE CELL; EPIGENETICS; FIBROGENESIS; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CARDIAC MUSCLE; CARDIOMYOPATHIES; DNA METHYLATION; FIBROSIS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC EPIGENESIS; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PROCEDURES; REGENERATION;

ANIMALS; CARDIOMYOPATHIES; COLLAGEN; DNA METHYLATION; EPIGENESIS, GENETIC; FIBROSIS; GENE EXPRESSION REGULATION; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC THERAPY; HUMANS; MICRORNAS; MYOCARDIUM; PHENOTYPE; REGENERATION;

EID: 85013955555     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25699     Document Type: Review

References (119)

1. Abonnenc M, Nabeebaccus AA, Mayr U, Barallobre-Barreiro J, Dong X, Cuello F, Sur S, Drozdov I, Langley SR, Lu R, Stathopoulou K, Didangelos A, Yin X, Zimmermann WH, Shah AM, Zampetaki A, Mayr M. 2013. Extracellular matrix secretion by cardiac fibroblasts: Role of microRNA-29b and microRNA-30c. Circ Res 113:1138–1147.
2. Almeida MI, Reis RM, Calin GA. 2011. MicroRNA history: Discovery, recent applications, and next frontiers. Mutat Res 717:1–8.
3. Angelini A, Li Z, Mericskay M, Decaux JF. 2015. Regulation of connective tissue growth factor and cardiac fibrosis by an SRF/MicroRNA-133a axis. PLoS ONE 10:e0139858.
4. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. 2012. Epigenetic protein families: A new frontier for drug discovery. Nat Rev Drug Discov 11:384–400.
5. 2 overload and cell death. J Clin Invest 122:1222–1232.
6. Bagnall RD, Tsoutsman T, Shephard RE, Ritchie W, Semsarian C. 2012. Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure. PLoS ONE 7:e44744.
7. Bannister A, Kouzarides T. 2011. Regulation of chromatin by histone modifications. Cell Res 21:381–395.
8. Bao MH, Feng X, Zhang YW, Lou XY, Cheng Y, Zhou HH. 2013. Let-7 in cardiovascular diseases, heart development and cardiovascular differentiation from stem cells. Int J Mol Sci 14:23086–23102.
9. Beaumont J, López B, Hermida N, Schroen B, San José G, Heymans S, Valencia F, Gómez-Doblas JJ, De Teresa E, Díez J, González A. 2014. MicroRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation. Clin Sci 126:497–506.
10. Besler C, Urban D, Watzka S, Lang D, Rommel KP, Kandolf R, Klingel K, Thiele H, Linke A, Schuler G, Adams V, Lurz P. 2016. Endomyocardial miR-133a levels correlate with myocardial inflammation, improved left ventricular function, and clinical outcome in patients with inflammatory cardiomyopathy. Eur J Heart Fail 18:1442–1451.
11. Bhattacharyya S, Ghosh AK, Pannu J, Mori Y, Takagawa S, Chen G, Trojanowska M, Gilliam AC, Varga J. 2005. Fibroblasts expression of the coactivator p300 governs the intensity of profibrotic response to TGF-β. Arthritis Rheum 52:1248–1258.
12. Bogaard HJ, Mizuno S, Hussaini AA, Toldo S, Abbate A, Kraskauskas D, Kasper M, Natarajan R, Voelkel NF. 2011. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med 183:1402–1410.
13. Bugyei-Twum A, Advani A, Advani SL, Zhang Y, Thai K, Kelly DJ, Connelly KA. 2014. High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. Cardiovasc Diabetol 13:89.
14. Castoldi G, Di Gioia CR, Bombardi C, Catalucci D, Corradi B, Gualazzi MG, Leopizzi M, Mancini M, Zerbini G, Condorelli G, Stella A. 2012. MiR-133a regulates collagen 1A1: Potential role of miR- 133a in myocardial fibrosis in angiotensin II-dependent hypertension. J Cell Physiol 227:850–856.
15. Chan HM, La Thangue NB. 2001. P300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 114:2363–2373.
16. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang DZ. 2006. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 38:228–233.
17. Chen S, Puthanveetil P, Feng B, Matkovich SJ, Dorn GW, 2nd, Chakrabarti S. 2014. Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes. J Cell Mol Med 18:415–421.
18. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, Wagner DR, Staessen JA, Heymans S, Schroen B. 2010. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 3:499–506.
19. Dancy BM, Cole PA. 2015. Protein lysine acetylation by p300/CBP. Chem Rev 115:2419–2452.
20. Demos-Davies KM, Ferguson BS, Cavasin MA, Mahaffey JH, Williams SM, Spiltoir JI, Schuetze KB, Horn TR, Chen B, Ferrara C, Scellini B, Piroddi N, Tesi C, Poggesi C, Jeong MY, McKinsey TA. 2014. HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling. Am J Physiol Heart Circ Physiol 307:H252–H258.
21. Denby L, Ramdas V, Lu R, Conway BR, Grant JS, Dickinson B, Aurora AB, McClure JD, Kipgen D, Delles C, van Rooij E, Baker AH. 2014. MicroRNA-214 antagonism protects against renal fibrosis. J Am Soc Nephrol 25:65–80.
22. Deng P, Chen L, Liu Z, Ye P, Wang S, Wu J, Yao Y, Sun Y, Huang X, Ren L, Zhang A, Wang K, Wu C, Yue Z, Xu X, Chen M. 2016. MicroRNA-150 inhibits the activation of cardiac fibroblasts by regulating c-Myb. Cell Physiol Biochem 38:2103–2122.
23. Dong H, Dong S, Zhang L, Gao X, Lv G, Chen W, Shao S. 2016. MicroRNA-214 exerts a cardio-protective effect by inhibition of fibrosis. Anat Rec (Hoboken) 299:1348–1357.
24. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, Herias V, van Leeuwen RE, Schellings MW, Barenbrug P, Maessen JG, Heymans S, Pinto YM, Creemers EE. 2009. MiR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 104:170–178.
25. Fang L, Ellims AH, Moore XL, White DA, Taylor AJ, Chin-Dusting J, Dart AM. 2015. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. J Transl Med 13:314.
26. Fernandes T, Baraúna VG, Negrão CE, Phillips MI, Oliveira EM. 2015. Aerobic exercise training promotes physiological cardiac remodeling involving a set of microRNAs. Am J Physiol Heart Circ Physiol 309:H543–H552.
27. Flynt AS, Li N, Thatcher EJ, Solnica-Krezel L, Patton JG. 2007. Zebrafish miR-214 modulates Hedgehog signaling to specify muscle cell fate. Nat Genet 39:259–263.
28. Frangogiannis NG. 2012. Regulation of the inflammatory response in cardiac repair. Circ Res 110:159–173.
29. García R, Nistal JF, Merino D, Price NL, Fernández-Hernando C, Beaumont J, González A, Hurlé MA, Villar AV. 2015. P-SMAD2/3 and DICER promote pre-miR-21 processing during pressure overload-associated myocardial remodeling. Biochim Biophys Acta 1852:1520–1530.
30. Ghosh AK, Bhattacharyya S, Lafyatis R, Farina G, Yu J, Thimmapaya B, Wei J, Varga J. 2013. P300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: Epigenetic feed-forward amplification of fibrosis. J Invest Dermatol 133:1302–1310.
31. Ghosh AK, Bhattacharyya S, Varga J. 2004. The tumor suppressor p53 abrogates Smad-dependent collagen gene induction in mesenchymal cells. J Biol Chem 279:47455–47463.
32. Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y, Varga J. 2009. Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J 23:2968–2977.
33. Ghosh AK, Mori Y, Dowling E, Varga J. 2007. Trichostatin A blocks TGF-beta-induced collagen gene expression in skin fibroblasts: Involvement of Sp1. Biochem Biophys Res Commun 354:420–426.
34. Ghosh AK, Nagpal V, Covington JW, Michaels MA, Vaughan DE. 2012. Molecular basis of cardiac endothelial-to-mesenchymal transition (EndMT): Differential expression of microRNAs during EndMT. Cell Signal 24:1031–1036.
35. Ghosh AK, Yuan W, Mori Y, Chen SJ, Varga J. 2001. Antagonistic regulation of Type I collagen gene expression by interferon-g and transforming growth factor-β: Integration at the level of p300/CBP transcriptional coactivators. J Biol Chem 276:11041–11048.
36. Ghosh AK, Yuan W, Mori Y, Varga J. 2000. Smad-dependent stimulation of Type I collagen gene expression in human skin fibroblasts by TGF-β involves functional cooperation with p300/CBP transcriptional coactivators. Oncogene 19:3546–3555.
37. Goodman RH, Smolik S. 2000. CBP/p300 in cell growth, transformation, and development. Genes Dev 14:1553–1577.
38. Gregoretti IV, Lee YM, Goodson HV. 2004. Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J Mol Biol 338:17–31.
39. Han W, Han Y, Liu X, Shang X. 2015. Effect of miR-29a inhibition on ventricular hypertrophy induced by pressure overload. Cell Biochem Biophys 71:821–826.
40. Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T, Shimokata K, Hasegawa Y. 2010. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 43:161–172.
41. Ikeda S, He A, Kong SW, Lu J, Bejar R, Bodyak N, Lee KH, Ma Q, Kang PM, Golub TR, Pu WT. 2009. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 29:2193–2204.
42. Iyer A, Fenning A, Lim J, Le GT, Reid RC, Halili MA, Fairlie DP, Brown L. 2010. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol 159:1408–1417.
43. Kang SH, Seok YM, Song MJ, Lee HA, Kurz T, Kim I. 2015. Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats. Mol Pharmacol 87:782–791.
44. Karakikes I, Chaanine AH, Kang S, Mukete BN, Jeong D, Zhang S, Hajjar RJ, Lebeche D. 2013. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc 2:e000078.
45. Kao YH, Liou JP, Chung CC, Lien GS, Kuo CC, Chen SA, Chen YJ. 2013. Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. Int J Cardiol 168:4178–4183.
46. Kee HJ, Bae EH, Park S, Lee KE, Suh SH, Kim SW, Jeong MH. 2013. HDAC inhibition suppresses cardiac hypertrophy and fibrosis in DOCA-salt hypertensive rats via regulation of HDAC6/HDAC8 enzyme activity. Kidney Blood Press Res 37:229–239.
47. Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR, Yin Z, Ahn Y, Jeong MH, Bang YJ, Kim N, Kim JK, Kim KK, Epstein JA, Kook H. 2006. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113:51–59.
48. Kishore R, Verma SK, Mackie AR, Vaughan EE, Abramova TV, Aiko I, Krishnamurthy P. 2013. Bone marrow progenitor cell therapy-mediated paracrine regulation of cardiac miRNA-155 modulates fibrotic response in diabetic hearts. PLoS ONE 8:e60161.
49. Krenning G, Zeisberg EM, Kalluri R. 2010. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 225:631–637.
50. Kumarswamy R, Volkmann I, Jazbutyte V, Dangwal S, Park DH, Thum T. 2012. Transforming growth factor-β-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. Arterioscler Thromb Vasc Biol 32:361–369.
51. Kuno A, Hori YS, Hosoda R, Tanno M, Miura T, Shimamoto K, Horio Y. 2013. Resveratrol improves cardiomyopathy in dystrophin-deficient mice through SIRT1 protein-mediated modulation of p300 protein. J Biol Chem 288:5963–5972.
52. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. 2001. Identification of novel genes coding for small expressed RNAs. Science 29:853–858.
53. Lai KB, Sanderson JE, Izzat MB, Yu CM. 2015. Micro-RNA and mRNA myocardial tissue expression in biopsy specimen from patients with heart failure. Int J Cardiol 199:79–83.
54. Lee RC, Feinbaum RL, Ambros V. 1993. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843–854.
55. Lee TM, Lin MS, Chang NC. 2007. Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. Am J Physiol Heart Circ Physiol 293:H968–H977.
56. Li HL, Liu C, de Couto G, Ouzounian M, Sun M, Wang AB, Huang Y, He CW, Shi Y, Chen X, Nghiem MP, Liu Y, Chen M, Dawood F, Fukuoka M, Maekawa Y, Zhang L, Leask A, Ghosh AK, Kirshenbaum LA, Liu PP. 2008. Curcumin prevents and reverses murine cardiac hypertrophy. J Clin Invest 118:879–893.
57. Liang H, Zhang C, Ban T, Liu Y, Mei L, Piao X, Zhao D, Lu Y, Chu W, Yang B. 2012. A novel reciprocal loop between microRNA-21 and TGFβRIII is involved in cardiac fibrosis. Int J Biochem Cell Biol 44:2152–2160.
58. Liu W, Liu Y, Zhang Y, Zhu X, Zhang R, Guan L, Tang Q, Jiang H, Huang C, Huang H. 2015a. MicroRNA-150 protects against pressure overload-induced cardiac hypertrophy. J Cell Biochem 116:2166–2176.
59. Liu X, Wang X, Bi Y, Bu P, Zhang M. 2015b. The histone demethylase PHF8 represses cardiac hypertrophy upon pressure overload. Exp Cell Res 335:123–134.
60. Lorenzen JM, Schauerte C, Hübner A, Kölling M, Martino F, Scherf K, Batkai S, Zimmer K, Foinquinos A, Kaucsar T, Fiedler J, Kumarswamy R, Bang C, Hartmann D, Gupta SK, Kielstein J, Jungmann A, Katus HA, Weidemann F, Müller OJ, Haller H, Thum T. 2015. Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis. Eur Heart J 36:2184–2196.
61. Marchand A, Proust C, Morange PE, Lompré AM, Trégouët DA. 2012. MiR-421 and miR-30c inhibit SERPINE 1 gene expression in human endothelial cells. PLoS ONE 7:e44532.
62. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, Stack C, Latimer PA, Olson EN, van Rooij E. 2011. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124:1537–1547.
63. Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, Nagasawa A, Komeda M, Fujita M, Shimatsu A, Kita T, Hasegawa K. 2008. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 118:868–878.
64. Nagalingam RS, Sundaresan NR, Noor M, Gupta MP, Solaro RJ, Gupta M. 2014. Deficiency of cardiomyocyte-specific microRNA-378 contributes to the development of cardiac fibrosis involving a transforming growth factor β (TGFβ1)-dependent paracrine mechanism. J Biol Chem 289:27199–27214.
65. Nagpal V, Rai R, Place AT, Murphy SB, Verma SK, Ghosh AK, Vaughan DE. 2016. MiR-125b is critical for fibroblast-to-myofibroblast transition and cardiac fibrosis. Circulation 133:291–301.
66. Nural-Guvener H, Zakharova L, Feehery L, Sljukic S, Gaballa M. 2015. Anti-fibrotic effects of class I HDAC inhibitor, mocetinostat is associated with IL-6/Stat3 signaling in ischemic heart failure. Int J Mol Sci 16:11482–11499.
67. Ogiwara H, Sasaki M, Mitachi T, Oike T, Higuchi S, Tominaga Y, Kohno T. 2016. Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression. Cancer Discov 6:430–445.
68. Pan Z, Sun X, Shan H, Wang N, Wang J, Ren J, Feng S, Xie L, Lu C, Yuan Y, Zhang Y, Wang Y, Lu Y, Yang B. 2012. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-β1 pathway. Circulation 126:840–850.
69. Parikh R, Kadowitz PJ. 2013. A review of current therapies used in the treatment of congestive heart failure. Expert Rev Cardiovasc Ther 11:1171–1178.
70. Pasipoularides A. 2015. Linking genes to cardiovascular diseases: Gene action and gene-environment interactions. J Cardiovasc Transl Res 8:506–527.
71. Patel SR, Kim D, Levitan I, Dressler GR. 2007. The BRCT-domain containing protein PTIP links PAX2 to a histone H3, lysine 4 methyltransferase complex. Dev Cell 13:580–592.
72. Patrick DM, Montgomery RL, Qi X, Obad S, Kauppinen S, Hill JA, van Rooij E, Olson EN. 2010. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 120:3912–3916.
73. Pchejetski D, Foussal C, Alfarano C, Lairez O, Calise D, Guilbeau-Frugier C, Schaak S, Seguelas MH, Wanecq E, Valet P, Parini A, Kunduzova O. 2012. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J 33:2360–2369.
74. Piek A, de Boer RA, Silljé HH. 2016. The fibrosis-cell death axis in heart failure. Heart Fail Rev 21:199–211.
75. Qiu P, Ritchie RP, Gong XQ, Hamamori Y, Li L. 2006. Dynamic changes in chromatin acetylation and the expression of histone acetyltransferases and histone deacetylases regulate the SM22α transcription in response to Smad3-mediated TGF-β1 signaling. Biochem Biophys Res Commun. 348:351–358.
76. Raut SK, Kumar A, Singh GB, Nahar U, Sharma V, Mittal A, Sharma R, Khullar M. 2015. MiR-30c mediates upregulation of Cdc42 and Pak1 in diabetic cardiomyopathy. Cardiovasc Ther 33:89–97.
77. Renaud L, Harris LG, Mani SK, Kasiganesan H, Chou JC, Baicu CF, Van Laer A, Akerman AW, Stroud RE, Jones JA, Zile MR, Menick DR. 2015. HDACs regulate miR-133a expression in pressure overload-induced cardiac fibrosis. Circ Heart Fail 8:1094–1104.
78. Roncarati R, Viviani Anselmi C, Losi MA, Papa L, Cavarretta E, Da Costa Martins P, Contaldi C, Saccani Jotti G, Franzone A, Galastri L, Latronico MV, Imbriaco M, Esposito G, De Windt L, Betocchi S, Condorelli G. 2014. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy andfibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 63:920–927.
79. Ryu SH, Park EY, Kwak S, Heo SH, Ryu JW, Park JH, Choi KC, Lee SW. 2016. Protective effect of α- lipoic acid against radiation-induced fibrosis in mice. Oncotarget 7:15554–15565.
80. Sang HQ, Jiang ZM, Zhao QP, Xin F. 2015. MicroRNA-133a improves the cardiac function and fibrosis through inhibiting Akt in heart failure rats. Biomed Pharmacother 71:185–189.
81. Satoh M, Minami Y, Takahashi Y, Tabuchi T, Nakamura M. 2010. Expression of microRNA-208 is associated with adverse clinical outcomes in human dilated cardiomyopathy. J Card Fail 16:404–410.
82. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. 2007. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 100:416–424.
83. Seeger T, Xu QF, Muhly-Reinholz M, Fischer A, Kremp EM, Zeiher AM, Dimmeler S. 2016. Inhibition of let-7 augments the recruitment of epicardial cells and improves cardiac function after myocardial infarction. J Mol Cell Cardiol 94:145–152.
84. Seok HY, Chen J, Kataoka M, Huang ZP, Ding J, Yan J, Hu X, Wang DZ. 2014. Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy. Circ Res 114:1585–1595.
85. Shyu KG, Wang BW, Cheng WP, Lo HM. 2015. MicroRNA-208a increases myocardial endoglin expression and myocardial fibrosis in acute myocardial infarction. Can J Cardiol 31:679–690.
86. Siedlecki P, Zielenkiewicz P. 2006. Mammalian DNA methyltransferases. Axta Biochemica Polonica 53:245–256.
87. Stein AB, Goonewardena SN, Jones TA, Prusick PJ, Bazzi AA, Belyavskaya JM, McCoskey MM, Dandar RA. 2015. The PTIP-associated histone methyltransferase complex prevents stress-induced maladaptive cardiac remodeling. PLoS ONE 10:e0127839.
88. Subramaniam D, Thombre R, Dhar A, Anant S. 2014. DNA methyltransferases: A novel target for prevention and therapy. Front Oncol 4:1–13.
89. Sun M, Yu H, Zhang Y, Li Z, Gao W. 2015. MicroRNA-214 mediates isoproterenol-induced proliferation and collagen synthesis in cardiac fibroblasts. Sci Rep 5:18351.
90. Sunagawa Y, Morimoto T, Wada H, Takaya T, Katanasaka Y, Kawamura T, Yanagi S, Marui A, Sakata R, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K. 2011. A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ J 75:2151–2159.
91. Sutton TA, Hato T, Mai E, Yoshimoto M, Kuehl S, Anderson M, Mang H, Plotkin Z, Chan RJ, Dagher PC. 2013. P53 is renoprotective after ischemic kidney injury by reducing inflammation. J Am Soc Nephrol 24:113–124.
92. Tao H, Yang JJ, Chen ZW, Xu SS, Zhou X, Zhan HY, Shi KH. 2014. DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2. Toxicology 323:42–50.
93. Tao H, Yang JJ, Hu W, Shi KH, Li J. 2016. HDAC6 promotes cardiac fibrosis progression through suppressing RASSF1A expression. Cardiology 133:18–26.
94. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S. 2008. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456:980–984.
95. Tijsen AJ, van der Made I, van den Hoogenhof MM, Wijnen WJ, van Deel ED, de Groot NE, Alekseev S, Fluiter K, Schroen B, Goumans MJ, van der Velden J, Duncker DJ, Pinto YM, Creemers EE. 2014. The microRNA-15 family inhibits the TGFβ-pathway in the heart. Cardiovasc Res 104:61–71.
96. Tolonen AM, Magga J, Szabó Z, Viitala P, Gao E, Moilanen AM, Ohukainen P, Vainio L, Koch WJ, Kerkelä R, Ruskoaho H, Serpi R. 2014. Inhibition of Let-7 microRNA attenuates myocardial remodeling and improves cardiac function postinfarction in mice. Pharmacol Res Perspect 2:e00056.
97. Tony H, Meng K, Wu B, Yu A, Zeng Q, Yu K, Zhong Y. 2015. MicroRNA-208a dysregulates apoptosis genes expression and promotes cardiomyocyte apoptosis during ischemia and its silencing improves cardiac function after myocardial infarction. Mediators Inflamm 2015:479123.
98. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN. 2006. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103:18255–18260.
99. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. 2007. Control of stress dependent cardiac growth and gene expression by a microRNA. Science 316:575–579.
100. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN. 2008. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 105:13027–13032.
101. Villar AV, García R, Merino D, Llano M, Cobo M, Montalvo C, Martín-Durán R, Hurlé MA, Nistal JF. 2013. Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients. Int J Cardiol 167:2875–2881.
102. Vujic A, Robinson EL, Ito M, Haider S, Ackers-Johnson M, See K, Methner C, Figg N, Brien P, Roderick HL, Skepper J, Ferguson-Smith A, Foo RS. 2015. Experimental heart failure modelled by the cardiomyocyte-specific loss of an epigenome modifier, DNMT3B. J Mol Cell Cardiol 82:174–183.
103. Wang X, Ha T, Zou J, Ren D, Liu L, Zhang X, Kalbfleisch J, Gao X, Williams D, Li C. 2014a. MicroRNA-125b protects against myocardial ischaemia/reperfusion injury via targeting p53-mediated apoptotic signalling and TRAF6. Cardiovasc Res 102:385–395.
104. Wang J, Huang W, Xu R, Nie Y, Cao X, Meng J, Xu X, Hu S, Zheng Z. 2012. MicroRNA-24 regulates cardiac fibrosis after myocardial infarction. J Cell Mol Med 16:2150–2160.
105. Wang Y, Wang Y, Luo M, Wu H, Kong L, Xin Y, Cui W, Zhao Y, Wang J, Liang G, Miao L, Cai L. 2015. Novel curcumin analog C66 prevents diabetic nephropathy via JNK pathway with the involvement of p300/CBP-mediated histone acetylation. Biochim Biophys Acta 1852:34–46.
106. Wang BW, Wu GJ, Cheng WP, Shyu KG. 2014b. MicroRNA-208a increases myocardial fibrosis via endoglin in volume overloading heart. PLoS ONE 9:e84188.
107. Watson CJ, Collier P, Tea I, Neary R, Watson JA, Robinson C, Phelan D, Ledwidge MT, McDonald KM, McCann A, Sharaf O, Baugh JA. 2014. Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype. Hum Mol Genet 23:2176–2188.
108. Watson CJ, Horgan S, Neary R, Glezeva N, Tea I, Corrigan N, McDonald K, Ledwidge M, Baugh J. 2016. Epigenetic therapy for the treatment of hypertension induced cardiac hypertrophy and fibrosis. J Cardiovasc Pharmacol Ther 21:127–137.
109. Weng X, Yu L, Liang P, Li L, Dai X, Zhou B, Wu X, Xu H, Fang M, Chen Q, Xu Y. 2015. A crosstalk between chromatin remodeling and histone H3K4 methyltransferase complexes in endothelial cells regulates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 82:48–58.
110. West AC, Johnstone RW. 2014. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124:30–39.
111. Wightman B, Ha I, Ruvkun G. 1993. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75:855–862.
112. Xu X, Tan X, Tampe B, Nyamsuren G, Liu X, Maier LS, Sossalla S, Kalluri R, Zeisberg M, Hasenfuss G, Zeisberg EM. 2015. Epigenetic balance of aberrant Rasal1 promoter methylation and hydroxymethylation regulates cardiac fibrosis. Cardiovasc Res 105:279–291.
113. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, Bronson RT, Li E, Livingston DM, Eckner R. 1998. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93:361–372.
114. Ye H, Ling S, Castillo AC, Thomas B, Long B, Qian J, Perez-Polo JR, Ye Y, Chen X, Birnbaum Y. 2013. Nebivolol induces distinct changes in profibrosis microRNA expression compared with atenolol, in salt-sensitive hypertensive rats. Hypertension 61:1008–1013.
115. Yu L, Yang G, Weng X, Liang P, Li L, Li J, Fan Z, Tian W, Wu X, Xu H, Fang M, Ji Y, Li Y, Chen Q, Xu Y. 2015. Histone methyltransferase SET1 mediates angiotensin II-induced endothelin-1 transcription and cardiac hypertrophy in mice. Arterioscler Thromb Vasc Biol 35:1207–1217.
116. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R. 2007. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 13:952–961.
117. Zhang Y, Huang XR, Wei LH, Chung AC, Yu CM, Lan HY. 2014. MiR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-β/Smad3 signaling. Mol Ther 22:974–985.
118. Zhao N, Koenig SN, Trask AJ, Lin CH, Hans CP, Garg V, Lilly B. 2015a. MicroRNA miR145 regulates TGFBR2 expression and matrix synthesis in vascular smooth muscle cells. Circ Res 116:23–34.
119. Zhao X, Wang K, Liao Y, Zeng Q, Li Y, Hu F, Liu Y, Meng K, Qian C, Zhang Q, Guan H, Feng K, Zhou Y, Du Y, Chen Z. 2015b. MicroRNA-101a inhibits cardiac fibrosis induced by hypoxia via targeting TGFβRI on cardiac fibroblasts. Cell Physiol Biochem 35:213–226.